News25/Ratings0
News · 26 weeks79+10%
2026-04-192026-10-11
Mix4590d
- Insider29(64%)
- Other9(20%)
- SEC Filings4(9%)
- Earnings2(4%)
- Leadership1(2%)
Latest news
25 items- INSIDERSEC Form 4 filed by Imunon Inc.4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERSEC Form 4 filed by Imunon Inc.4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERSEC Form 4 filed by Imunon Inc.4 - Imunon, Inc. (0000749647) (Issuer)
- PRIMUNON to Participate in Upcoming Investor ConferencesLAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer, will participate in the following October 2026 investor conferences. Maxim Growth Summit 2026Date: October 12 - 14, 2026Location: Hard Rock Hotel, New York, NYPresentation: Oncology Panel, October 14, 2026, at 9:00 a.m. ET For more information and a complete agenda of the Maxim Growth Summit, please visit https://www.maximgrp.com/2026-growth-summit. 2026 ThinkEquity ConferenceDate: October 15, 2026Location: Mandarin Oriental Hotel, New York, NYP
- SECImunon Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Imunon, Inc. (0000749647) (Filer)
- PRIMUNON Converts $1.2 Million of Debt-to-EquityUnique investment vehicle provides efficient access to equity capitalOutstanding debt of the original Note lowered by approximately 43% No issuance of common stock or dilutive warrants LAWRENCEVILLE, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), ("IMUNON" or the "Company"), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that it has entered into an Exchange Agreement, under which $1.2 million of outstanding debt, together with accrued and unpaid interest, was exchanged for shares of the Company’s newly designated, non-convertible Series B Preferred Stock. The transaction reduces the Company’s outstanding debt by approx
- INSIDERExecutive Chairman of Board Tardugno Michael H was granted 7,169 shares, increasing direct ownership by 7% to 103,921 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERPresident and CEO Lindborg Stacy was granted 6,697 shares, increasing direct ownership by 6% to 113,197 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERChief Medical Officer Faller Douglas Vincent was granted 4,390 shares, increasing direct ownership by 11% to 45,678 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- PRIMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory readout in OVATION 3 Testimonial conversation with an OVATION 1 participant now 10 years from diagnosis LAWRENCEVILLE, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today is presenting an update on its IMNN-001 development program for women with newly diagnosed advanced ovarian cancer. The program reviews final overall survival results from the randomized Phase 2 OVATION 2 Study, preliminary cli
- PRIMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety ReviewIndependent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date No cytokine release syndrome, systemic toxicities or serious immune-related adverse events observed to date, reinforcing IMNN-001's differentiated safety profile as an IL-12-based immunotherapy MRD study has now demonstrated the safety and tolerability of IMNN-001 both in combination with bevacizumab and in the maintenance setting Recommendation follows encouraging preliminary Phase 2 MRD data reported in July demonstrating evidence of deeper anti-tumor activity and immune activation LAWRENCEVILLE, N.J., Sept. 22, 2026 (GLOBE NEWSW
- INSIDERExecutive Chairman of Board Tardugno Michael H was granted 5,824 shares, increasing direct ownership by 6% to 95,699 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERPresident and CEO Lindborg Stacy was granted 5,504 shares, increasing direct ownership by 5% to 105,580 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERChief Medical Officer Faller Douglas Vincent was granted 4,211 shares, increasing direct ownership by 11% to 41,288 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- PRIMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens IMUNON retains ownership of its background intellectual property with an opportunity to expand its IP through this collaboration LAWRENCEVILLE, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health. Under the CRADA, IMUNON and the NCI’s Cancer Therapy Evaluation Program (CTEP) who assumes re
- PRIMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical ProgressInvestors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced the agenda and speaker lineup for its upcoming R&D Day highlighting IMNN-001, the Company’s investigational IL-12 immunotherapy. The event will be held at the Sofitel New York in New York City on Wednesday, September 23, 2026, beginning at 10:00 a.m. ET. To register to attend the event in person or virtually, please RSVP by clicking here. "We look forward to ga
- INSIDERExecutive Chairman of Board Tardugno Michael H was granted 7,371 shares, increasing direct ownership by 9% to 89,875 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERPresident and CEO Lindborg Stacy was granted 6,822 shares, increasing direct ownership by 7% to 100,076 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERChief Medical Officer Faller Douglas Vincent was granted 3,626 shares, increasing direct ownership by 11% to 37,077 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERGeneral Counsel and Corp Sec Eylward Susan was granted 2,525 shares and sold $3,950 worth of shares (2,525 units at $1.56) (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- PRIMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones A patient treated with IMNN-001 will share firsthand perspective on her treatment journey and life following participation in the clinical trial The event will be held on September 23 in New York City and will be webcast live LAWRENCEVILLE, N.J., Aug. 26, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company developing IMNN-001 DNA-mediated IL-12 immunotherapy, today announced that it will host an R&D Day for investors, analysts and media on Wednesday, September 23, 2026, at the Sofitel New
- INSIDERPresident and CEO Lindborg Stacy was granted 6,615 shares, increasing direct ownership by 8% to 93,254 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERChief Medical Officer Faller Douglas Vincent was granted 3,516 shares, increasing direct ownership by 12% to 33,451 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERExecutive Chairman of Board Tardugno Michael H was granted 7,147 shares, increasing direct ownership by 9% to 82,504 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERGeneral Counsel and Corp Sec Eylward Susan was granted 2,449 shares and sold $3,993 worth of shares (2,449 units at $1.63) (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
IMNN FAQ
4 questionsWhere does IMNN stock trade?
Imunon Inc. (IMNN) is listed on NASDAQ.What sector and industry is IMNN in?
Imunon Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to IMNN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IMNN side-by-side with any of them on Quantisnow.How can I track IMNN on Quantisnow?
Quantisnow aggregates Imunon Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMNN to receive live email and push alerts on every new disclosure.